stoxline Quote Chart Rank Option Currency Glossary
  
Protagenic Therapeutics, Inc. (PTIX)
5.37  -0.77 (-12.54%)    05-22 16:00
Open: 6.27
High: 6.3067
Volume: 903,252
  
Pre. Close: 6.14
Low: 5.2
Market Cap: 3(M)
Technical analysis
2025-05-22 4:50:33 PM
Short term     
Mid term     
Targets 6-month :  11.35 1-year :  16.67
Resists First :  9.72 Second :  14.27
Pivot price 4.29
Supports First :  2.34 Second :  1.95
MAs MA(5) :  6.5 MA(20) :  4
MA(100) :  4.54 MA(250) :  7.92
MACD MACD :  0.6 Signal :  0.3
%K %D K(14,3) :  31.6 D(3) :  42.9
RSI RSI(14): 53.8
52-week High :  25.84 Low :  2.34
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ PTIX ] has closed below upper band by 37.7%. Bollinger Bands are 239.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 6.31 - 6.37 6.37 - 6.4
Low: 5.11 - 5.16 5.16 - 5.19
Close: 5.31 - 5.38 5.38 - 5.43
Company Description

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.

Headline News

Wed, 21 May 2025
Protagenic Therapeutics raises $3.1 million from warrants By Investing.com - Investing.com South Africa

Wed, 21 May 2025
Protagenic Therapeutics Receives $3.1 Million from Recent Warran - GuruFocus

Wed, 21 May 2025
Fresh $3.1M Funding Boosts Protagenic Therapeutics CNS Drug Pipeline After Major Merger - Stock Titan

Tue, 20 May 2025
Protagenic Therapeutics Merges With Phytanix Bio In All-Stock Deal: Retail Turns Extremely Bullish - MSN

Mon, 19 May 2025
Protagenic Therapeutics (PTIX) Stock Soars 240% On Phytanix Merger - Benzinga

Mon, 19 May 2025
PTIX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Protagenic Therapeutics, Inc. Is Fair to Shareholders - Business Wire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 1 (M)
Shares Float 0 (M)
Held by Insiders 16.5 (%)
Held by Institutions 4.7 (%)
Shares Short 17 (K)
Shares Short P.Month 5 (K)
Stock Financials
EPS -15.82
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.96
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -113.5 %
Return on Equity (ttm) -236.1 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -10.52
Qtrly Earnings Growth 0 %
Operating Cash Flow -4 (M)
Levered Free Cash Flow -2 (M)
Stock Valuations
PE Ratio -0.34
PEG Ratio 0
Price to Book value 2.73
Price to Sales 0
Price to Cash Flow -0.69
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android